Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Mononen

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1991
Aspartylglycosaminuria in the Finnish population: identification of two point mutations in the heavy chain of glycoasparaginaseI Mononen, N Heisterkamp, V Kaartinen, et al.
Journal of Internal Medicine|March 1, 1992
Prevalence and geographical distribution of major LDL receptor gene rearrangements in FinlandK Aalto-Setälä, U M Koivisto, T A Miettinen, et al.
Journal of Inherited Metabolic Disease|May 30, 2008
Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parametersJ W Koskenvuo, J J Hartiala, P Nuutila, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1991
Aspartylglycosaminuria in the Finnish population: identification of two point mutations in the heavy chain of glycoasparaginaseI Mononen, N Heisterkamp, V Kaartinen, et al.
Journal of Internal Medicine|March 1, 1992
Prevalence and geographical distribution of major LDL receptor gene rearrangements in FinlandK Aalto-Setälä, U M Koivisto, T A Miettinen, et al.
Journal of Inherited Metabolic Disease|May 30, 2008
Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parametersJ W Koskenvuo, J J Hartiala, P Nuutila, et al.
Pageof 7